Efficacy and Safety of Aflibercept 8 mg in PULSAR Trial in Neovascular AMD

Opinion
Video

Dr. Marion Munk reviews the Phase 3 clinical trial of high-dose aflibercept (8 mg) in neovascular AMD, emphasizing how this new therapy could alleviate the treatment burden for patients while providing superior outcomes.

Recent Videos
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Giulia Corradetti, MD, discusses her presentation "Functional Microperimetric Correlates of OCT Structures Features in Intermediate AMD"
Marion Munk, MD, PhD, presenting slides
Ash Abbey, MD, shares 36-month data from the GALE study of pegcetacoplan
Antonio Filipe Macedo, OD, MSc, PhD, speaks about the 2024 ARVO meeting
Related Content
A large vertical banner, indicating the headquarters of the European Commission, hanging on the southern wing of the Berlaymont building. Image credit: ©olrat – stock.adobe.com

European Commission grants marketing authorisation for aflibercept biosimilar Afqlir (Sandoz Group)

Sydney M Crago
November 15th 2024
Article

The biosimilar to reference aflibercept (Eylea, Bayer AG) is indicated to treat retinal diseases including neovascular age-related macular degeneration

Light therapy: Potential treatment for dry AMD

Light therapy: Potential treatment for dry AMD

Lynda Charters
October 18th 2024
Article

Non-invasive, painless laser can reduce risk of vision loss

Intravitreal injections for AMD and DME may complicate cataract surgery

Intravitreal injections for AMD and DME may complicate cataract surgery

Lynda Charters
October 18th 2024
Article

A large study performed in Canada analyzed data and found that patients are at higher risk of multiple possible complications after cataract surgery.

A phone and computer with the European Medicines Agency website. Image credit: ©Timon – stock.adobe.com

EU CHMP confirms negative opinion on marketing authorisation application of intravitreal pegcetacoplan from Apellis

Martin David Harp
September 25th 2024
Article

The agency confirmed its June 2024 negative opinion after Apellis requested re-examination of the EMA's initial response

A cell being injected by a syringe. Image credit: ©Corona Borealis – stock.adobe.com

Trinity team’s gene therapy offers promising glaucoma and AMD treatment

Martin David Harp
September 9th 2024
Article

Research by investigators at Trinity College in Dublin, Ireland shows how the gene therapy conferred significant protection for retinal ganglion cells

The US FDA logo on a laptop screen. Image credit: ©monticellllo – stock.adobe.com

US FDA issues approval for Sandoz aflibercept-abzv (Enzeevu)

David Hutton
August 12th 2024
Article

The biosimilar is indicated to improve and maintain visual acuity for patients with neovascular age-related macular degeneration

© 2024 MJH Life Sciences

All rights reserved.